Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

被引：47
|
作者：
Lv, Meng [1 ]
Huang, Xiao-Jun [1 ]
机构：
[1] Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2012年 / 5卷
基金：
中国国家自然科学基金;
关键词：
China; Allo-HSCT; Haploidentical; Relapse; GVHD; Elderly patients; ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; RISK ACUTE-LEUKEMIA; ACUTE GVHD; ANTITHYMOCYTE GLOBULIN; MYCOPHENOLATE-MOFETIL; CLINICAL-OUTCOMES; T-CELLS; BLOOD;
D O I：
10.1186/1756-8722-5-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
    Meng Lv
    Xiao-Jun Huang
    Journal of Hematology & Oncology, 5
  • [2] Hematopoietic stem cell transplantation for pediatric autoimmune disease: where we stand and where we need to go
    Krauss, A. C.
    Kamani, N. R.
    BONE MARROW TRANSPLANTATION, 2009, 44 (03) : 137 - 143
  • [3] Hematopoietic stem cell transplantation for pediatric autoimmune disease: where we stand and where we need to go
    A C Krauss
    N R Kamani
    Bone Marrow Transplantation, 2009, 44 : 137 - 143
  • [4] Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?
    Potdar, Rashmika
    Varadi, Gabor
    Fein, Joshua
    Labopin, Myriam
    Nagler, Arnon
    Shouval, Roni
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (11) : 1839 - 1846
  • [5] Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
    Fleischman, Angela G.
    Maziarz, Richard T.
    CURRENT OPINION IN HEMATOLOGY, 2013, 20 (02) : 130 - 136
  • [6] Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?
    Giralt, Sergio
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (09) : 793 - +
  • [7] Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
    More, Sonia
    Corvatta, Laura
    Manieri, Valentina Maria
    Saraceni, Francesco
    Scortechini, Ilaria
    Mancini, Giorgia
    Fiorentini, Alessandro
    Olivieri, Attilio
    Offidani, Massimo
    CELLS, 2022, 11 (04)
  • [8] Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: Where Are We Now and Which Way Should We Go?
    Le Gouill, Steven
    Mohty, Mohamad
    Guillaume, Thierry
    Gastinne, Thomas
    Moreau, Philippe
    SEMINARS IN HEMATOLOGY, 2011, 48 (03) : 227 - 239
  • [9] Depression and survival after hematopoietic stem cell transplantation: Where do we go from here?
    Andrykowski, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5878 - 5880
  • [10] Gut microbiota and hematopoietic stem cell transplantation: where do we stand?
    Zama, D.
    Biagi, E.
    Masetti, R.
    Gasperini, P.
    Prete, A.
    Candela, M.
    Brigidi, P.
    Pession, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (01) : 7 - 14
12345